Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses safety results from the MagnetisMM-3 trial (NCT04649359), a Phase II, open-labeled, multicenter, non-randomized trial evaluating elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody in patients with relapsed/refractory multiple myeloma. Patients enrolled were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Preliminary results of MagnetisMM-3 in patients with relapsed/refractory myeloma and no prior BCMA-targeted treatment suggest that 76 mg of elranatamb adminstered once weekly with a 2-step-up priming regimen is well tolerated, with no grade 3 cytokine release syndrome or immune effector cell-assciated neurotoxicity syndrome (ICANS) observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses current and upcoming treatment combinations in multiple myeloma, drawing focus on immunotherapies. Dr Costa first highlights the promise of CAR-T therapy, and then goes on to discuss bispecific T-cell engagers (BiTEs). Other promising approaches in this field include monoclonal antibodies, and Dr Costa highlights some clinical trials investigating the earlier use of these agents, such as the MajesTEC-1 (NCT04557098) and MagnetisMM-3 (NCT04649359) trials. To conclude, Dr Costa discusses the role of BCL2 inhibitors and their place in the myeloma treatment landscape. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.